Skip to main content

Table 1 Univariable Cox proportional hazards analysis of survival based on genetic aberration in the two cohorts

From: Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

Genetic aberration

Overall survival in discovery cohort

Overall survival in validation cohort

Radiographic progression-free survival in discovery cohort

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

AR aberration

3.87 (2.21–6.77)

< 0.001

2.26 (1.43–3.58)

<0.001

1.86 (1.07–3.24)

0.028

TP53 aberration

3.55 (2.07–6.08)

< 0.001

2.18 (1.37–3.47)

0.001

1.80 (1.01–3.13)

0.039

RB1 deletion

4.10 (2.33–7.22)

< 0.001

1.79 (1.09–2.94)

0.021

3.08 (1.64–5.79)

< 0.001

PI3K aberration

2.66 (1.55–4.58)

< 0.001

2.11 (1.33–3.34)

0.002

2.53 (1.42–4.49)

0.001

  1. All p-values < 0.05 are highlighted in bold
  2. Data regarding radiographic progression-free survival was not available for the validation cohort
  3. CI confidence interval, HR hazard ratio, PI3K phosphatidylinositol-3-kinase